Aligos Therapeutics, Inc. (ALGS) Bundle
A Brief History of Aligos Therapeutics, Inc. (ALGS)
Company Overview
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company founded in 2018 and headquartered in South San Francisco, California.
Financial Performance
| Fiscal Year | Revenue | Net Loss | Cash Position |
|---|---|---|---|
| 2022 | $0.3 million | $84.7 million | $110.1 million |
| 2023 | $0.2 million | $62.4 million | $75.6 million |
Stock Performance
As of January 2024, ALGS stock price ranges between $1.50 and $2.50 per share.
Research Focus Areas
- Hepatitis B virus (HBV) therapeutics
- COVID-19 antiviral treatments
- Liver disease therapies
Key Clinical Programs
| Program | Development Stage | Indication |
|---|---|---|
| ALG-010133 | Phase 2 | Hepatitis B |
| ALG-020572 | Phase 1 | Liver Disease |
Funding and Investments
Total funding raised: $250.5 million through venture capital and public offerings as of 2023.
Leadership
- Jack Nielsen - CEO
- Adam Henegar - CFO
- Lawrence Blatt - Chairman
A Who Owns Aligos Therapeutics, Inc. (ALGS)
Major Institutional Shareholders
| Shareholder | Shares Owned | Percentage |
|---|---|---|
| venBio Select Advisor LLC | 2,353,611 | 16.4% |
| Orbimed Advisors LLC | 1,845,239 | 12.9% |
| Federated Hermes Inc | 1,256,187 | 8.8% |
Executive Leadership Ownership
- Adam R. Friedman - President and CEO - 186,789 shares
- William Collier - Chief Financial Officer - 54,321 shares
- Jack Higgins - Chief Medical Officer - 42,567 shares
Insider Ownership Percentage
Total insider ownership: 7.2%
Public Float
Total shares outstanding: 14,327,456
Ownership Distribution
- Institutional investors: 62.3%
- Retail investors: 30.5%
- Insiders: 7.2%
Aligos Therapeutics, Inc. (ALGS) Mission Statement
Company Overview
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for viral diseases and liver disorders.
| Ticker Symbol | Headquarters | Founded | Market Cap |
|---|---|---|---|
| ALGS | South San Francisco, CA | 2018 | $85.2 million (as of January 2024) |
Research Focus Areas
- Hepatitis B virus (HBV) therapeutics
- COVID-19 antiviral treatments
- Liver disease therapies
Key Pipeline Programs
| Program | Indication | Clinical Stage |
|---|---|---|
| ALG-010133 | Hepatitis B | Phase 2 |
| ALG-020572 | COVID-19 | Phase 1 |
Financial Performance
| Metric | 2023 Value |
|---|---|
| Cash and Cash Equivalents | $93.4 million |
| Research and Development Expenses | $63.2 million |
| Net Loss | $71.5 million |
Strategic Objectives
- Advance HBV therapeutic development
- Progress COVID-19 antiviral research
- Optimize clinical trial strategies
- Maintain robust financial resources
Research Approach
Proprietary drug discovery platforms targeting viral replication mechanisms and liver disease pathways.
How Aligos Therapeutics, Inc. (ALGS) Works
Company Overview
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for viral diseases and liver disorders.
Financial Performance
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | $0.5 million |
| Net Loss | $64.3 million |
| Cash and Cash Equivalents | $79.4 million (as of September 30, 2023) |
Key Research Areas
- Hepatitis B Virus (HBV) therapeutics
- COVID-19 treatment development
- Liver disease interventions
Clinical Pipeline
| Program | Development Stage | Target Indication |
|---|---|---|
| ALG-010133 | Phase 2 Clinical Trial | Hepatitis B Virus |
| ALG-020572 | Preclinical Stage | COVID-19 |
Stock Performance
NASDAQ ticker symbol: ALGS
| Stock Metric | Current Value |
|---|---|
| Stock Price | $1.23 (as of January 2024) |
| Market Capitalization | $56.7 million |
Research and Development Expenses
R&D spending for 2023: $52.6 million
Corporate Structure
- Headquartered in South San Francisco, California
- Approximately 75 employees
- Founded in 2012
How Aligos Therapeutics, Inc. (ALGS) Makes Money
Revenue Streams
As of 2024, Aligos Therapeutics generates revenue primarily through:
- Research and development collaborations
- Potential licensing agreements
- Grant funding
Financial Performance
| Financial Metric | Amount (USD) | Year |
|---|---|---|
| Total Revenue | $4.7 million | 2022 |
| Net Loss | $78.4 million | 2022 |
| Cash and Cash Equivalents | $101.3 million | December 31, 2022 |
Research Focus Areas
Aligos concentrates on developing therapies in specific therapeutic areas:
- Liver diseases
- Viral infections
- Hepatitis B
- COVID-19 treatments
Pipeline Development
The company's potential revenue generation is linked to its drug development pipeline, with key programs in clinical stages.
| Program | Development Stage | Potential Market |
|---|---|---|
| ALG-020572 (Liver Disease) | Phase 2 | Hepatitis B |
| ALG-055009 (Viral Treatment) | Preclinical | COVID-19 |
Research Funding
Aligos secures funding through:
- Public offerings
- Private placements
- Research grants
Operational Expenses
| Expense Category | Amount (USD) | Year |
|---|---|---|
| Research and Development | $62.3 million | 2022 |
| General and Administrative | $16.1 million | 2022 |
Aligos Therapeutics, Inc. (ALGS) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.